Two presenters, one male & one female. The two hosts are in the same location on the same set. ....................................................................................... Male Host: “Good morning.” Female Host: “And a good morning to you too... and good morning everyone.” Male Host: “Today we want to talk about that dreaded subject ... cancer. I am sure we all know someone who has had cancer?” Female Host: “We certainly do... it has directly touched my family, that’s for sure.” Male Host: “I don’t think there is any family that has not been touched by cancer. But you know that old saying;... for every dark cloud there is a silver lining?” Female Host: “Yes, and I want to hear about the silver lining please. ” Male Host: cancer early.” “Well, today, we will tell you some good news about the importance of diagnosing Female Host: “Yes, that is very important, because cancer specialists all over the world all agree on one particular thing ... the very best way to survive cancer is early detection.” Male Host: cancer.” “You are 100% right, finding cancer early is without any doubt, the best way to survive Female Host: “Yes it is, because nobody in the world is immune to cancer!” Male Host: “You are absolutely right! We read the names in the headlines all the time don’t we... Steve Jobs, Olivia Newton- John, Jimmy Carter, Henry Ford, David Bowie, Allen Ginsberg, Jacqueline Kennedy- Onassis, Marlon Brando, Bob Marley, Patrick Swayze, Larry King, Freud, Pele, Oppenheimer, Pavarotti ... and I could go on and on..." Female Host: “Even Charles, the King of England, and Kate Middleton, the Princess of Wales, have both recently been diagnosed with cancer”. Male Host: “Yes, so you see, it doesn’t matter who you are, a King or a Queen, young or old, black or white, rich and famous... or poor and not so famous... it just doesn’t matter... because cancer is not discerning... there isn’t a person on the planet who is immune to cancer.” Female Host: “I read a statistic that half the World’s population will be diagnosed with cancer in their lifetime. That’s one out of every two people... think about it, that means that one of us is going to get cancer! That’s a really scary thought.” Male Host: “It certainly is! Very very sobering. I also read a statistic that said heart disease is the number one killer in the world today and that cancer is number two. That’s also scary to me, because there are life-style choices we can make to mitigate the onset of heart disease, but there is absolutely nothing at all any of us can do to lower the risk of cancer. Even the fittest and healthiest among us can succumb to cancer. Now that’s scary!” Female Host: “It surely is... So what does that mean? It means it’s really true when cancer scientists tell us that the best way to survive cancer is ‘early detection’” Male Host: “Again, you are 100% right!! So today we want to share with you the silver lining to the cancer pandemic that seems to touch all of our lives in one way or another. We want to tell you about an Australian company called Cancer Screen Technologies. They are at the forefront of global cancer diagnostic technologies... in other words, the early detection of cancer.” Female Host: “Cancer Screen Technologies, (or CST for short), has a commercially proven, FDA approved, cancer blood test that is ready for large scale manufacturing. But more importantly ...” Male Host: “Sorry to interrupt, but I think what you are about to say is the big news for everyone listening or watching today...” Female Host: “Yes, it surely is... CST has invented and developed a saliva based cancer test. This saliva cancer test is unique in the world, because it is the only point-of-care or over-the-counter cancer test in the world today that can use a simple saliva sample to quickly, cheaply - but reliably, detect multiple types of cancer right at the Doctor’s clinic or hospital ... “ Male Host: “Or even one day, in the comfort of your own home.” Female Host: “Yes, and CST’s test can currently detect up to twenty four major cancers.” Male Host: “That is a remarkable development.” Female Host: “It really is...” Male Host: “I also read that CST’s test is also predictive of the actual stage of cancer?” Female Host: “You are right... and this is the exciting part because this is the absolute key to early detection. If you can detect cancer at stage one for example, which by the way is very hard to do, then your chances of surviving cancer is dramatically increased.” Male Host: “Yes, the chances of survival increases up to 900% if your cancer can be found early . Let that number sink in... 900%!” Female Host: “That’s how critically important this is...” Male Host: to do?” “So wouldn’t you just take the test every six months if it is such a cheap and easy test Female Host: “Exactly! We are all familiar with COVID rapid testing now right?” Male Host: “Yes we are...” Female Host: “So, how easy and convenient would it be to do a cancer test every so often, if it means you have a survival rate for stage 1 cancer exceeding 90%... as opposed to stage 4 which drops to around 10%? That’s not rocket science, and it’s not even a questionable choice really!” Male Host: “I agree. And it is not as if CST’s test is restricted to one cancer like almost every other test. CST’s test can detect up to 24 major cancers, so you are getting a broad screening for cancer types every time you test.” Female Host: “Exactly... With all of this background information to support CST’s cancer test, and knowing your chances of survival increases up to 900%, if you can detect cancer early, you would never even question whether or not to take CST’s cancer test every six months or so.” Male Host: “Absolutely. So what are CST’s products?” Female Host: “Well, first of all, and I think this is very important to note, CST already has an FDA approved ELISA test which uses blood to test for cancer. For those of you who don’t know, an ELISA test simply uses an ELISA machine to process test results. Every major laboratory and hospital in the world will have an ELISA machine. This ELISA cancer test of CST’s is already commercially proven and is ready for large scale manufacturing.” Male Host: “That is an important distinction to make and to understand about CST’s products... it is already a commercially proven technology with FDA approval.” Female Host: “Yes, it is a well proven technology with not only FDA approval, but successful clinic trials of 14,770 subjects all over the world... in America, Australia, Canada, China, Germany, Malaysia, Singapore, South Korea, etc.” Male Host: “That certainly is a well proven technology. So what about CST’s saliva cancer test?” Female Host: reasons. “Well, the saliva test is divided into two separate products for a couple of very good The first saliva cancer test is what CST calls its Phase 1 test. It is a mass-population, rapid Point-of-Care/Over-the-Counter saliva cancer test. This is a quick ‘Yes’ or ‘No’ answer. Think of this as the first line of defence... do I have cancer or not?” Male Host: “So will this test be phased out or replaced?” Female Host: “No. Think of the Phase 1 test this way... it will always be available as a mass- population screening test, because it can quickly provide anyone, anywhere, with a cheap but accurate ‘yes’ or ‘no’ result – just like a pregnancy test or a COVID test... whether that person is in a first world country or a third world country. Male Host: “I understand the importance of such a test now. So what is Phase 2?” Female Host: “CST’s Phase 2 saliva cancer test is a rapid point-of-care saliva device. It can provide ‘yes’ or ‘no’ answers, but with the assistance of Artificial Intelligence, it provides very comprehensive analysis of not only the cancer, but it can also provide personalised treatment tailored to an individual’s DNA ...” Male Host: “Such as their body’s reception to different types of medication?” Female Host: “Yes exactly... what medication or treatment will work or not work with that patient. Personalised Medicine... which is the future of medicine and treating patients.” Male Host: “Yes...it certainly is going to be.” Female Host: “But it is also about the patient’s medical predispositions... meaning, other ailments or medication that may inhibit or otherwise negate prescribed treatments. Everybody is different. We are just learning that.” Male Host: “So the Phase 1 saliva cancer test really represents a revolution in Cancer testing, because it takes cancer testing to the masses?” Female Host: “Yes, the Phase 1 saliva test takes cancer testing into the world of over-the-counter convenience... and ease of use. Cheap, fast and accurate... for anybody, anywhere, any time.” Male Host: treatment?” “And the Phase 2 device is a seamless transition from cancer detection to personalised Female Host: “Yes, that is correct... the Phase 2 device combines a cost-effective point-of-care approach, with artificial intelligence assisted clinical analysis on a single platform to tailor treatment for each individual patient... personalised medicine... which is the future of medicine.” Male Host: “And that future is a very big market. The W.H.O. estimates the global In-Vitro diagnostic market to be a 130 billion dollar business by 2033.” Female Host: “That’s billion with a ‘B’ ... So what are the forecasted key financials of CST’s share of that business?” Male Host: “Well... CST has conservatively forecast its share of the global IVD market at only 0.13% of global sales, and only 0.31% of the global testing business. I don’t think anyone could contend they are not conservative numbers.” Female Host: “I absolutely agree, they are very conservative.” Male Host: “CST aims to be cash-flow positive by Q4 of year 2, with a gross profit margin in year 5 of 85% and an operating profit margin in year 5 of 71%. Female Host: “That’s impressive.” Male Host: “Yes, and so are CST’s projections. Blood Test kit revenues will be generated in Q4 of year 1. Phase 1 Saliva Test revenues in Q4 of year 2 and Phase 2 Saliva Test device revenues in Q4 of year 3. EBT is projected to be 111 Million dollars in year 5, with net operating cash flow of 122 Million dollars. Cumulative net cash flow is projected to be 192 Million dollars in year 5 with a valuation of CST at that time of 558 Million dollars.” Female Host: “Again, very impressive numbers. So what is CST looking for now?” Male Host: “CST is conducting a working capital raise of a minimum of 18.5 Million dollars. This will be by way of an equity participation and/or a convertible note... investors can choose whatever option they would like or any combination of options.” Female Host: “What will the funds be used for?” Male Host: “Manufacturing, commercialisation and finalisation of products.” Female Host: “Has CST been independently valued for this capital raising?” Male Host: “Yes, CST was independently valued in November 2024 by one of the largest, oldest and most reputable auditors, accounting and advisory firms in Australia. On a discounted cash flow basis of 40%, which is conservative I must say, CST was valued, on a pre-money basis, at 54 Million dollars.” Female Host: “I read somewhere, or perhaps you already told me (Female Host laughs), that CST is planning the perfect exit strategy for investors as well?” Male Host: “Well, I haven’t told you yet, so your cognitive capacity is intact (Male Host laughs), but yes, CST is currently laying the foundations for an Australian Stock Exchange listing via a potential reverse takeover of an ASX listed company. CST’s management indicate this should be executed in the latter half of this year.” I believe you were impressed by CST’s management team?” Female Host: “Well, as you know, a company is only as good as its management, and CST has put together an excellent leadership team with some of the most qualified professionals in the industry from around the world. I was impressed.” Male Host: “So what are the benefits to an investor if they put their trust in CST’s management team and invest in CST?” Female Host: “That is pretty easy to answer really. Firstly, CST meets every criteria for ESG framework investing to generate stakeholder value. Secondly, there is the possibility of entrepreneurial rates of return. For example, not only does the product speak for itself commercially, especially when you evaluate the sales potential of a product like CST’s, but you must add to that potential an ASX listing that will capitalise CST’s market value. Thirdly, CST is entitled to Australian Tax Office Early Stage Innovation Company status, which provide regulated tax rebates and 100% capital gains exemptions for 10 years. And finally, on a consolidated basis, the group has invested 90 Million dollars in research and development to bring CST’s products to where they are today for the benefit of new investors.” Male Host: “You have convinced me! But what is CST’s strategy with regard to marketing and distribution? In other words, do they have a viable business plan to get their products to market?” Female Host: “I am glad you asked, because this is something I focused on in CST’s business plan. In my mind, marketing and distribution are the keys to success for every company with a new product. No sales, no company... (Female Host laughs). Initially CST will focus on the home of 3.5 Billion people... India, China, Indonesia, South Korea, Taiwan, Japan, Indonesia, Philippines, Vietnam, Thailand, Malaysia, Singapore... and of course, Australia and New Zealand. There are a few very practical and logical reasons for this focus on Asia. Firstly, some of these countries have some of the highest cancer rates in the world. Secondly, in a financial context, if 1 out of every 2 people in these countries develop cancer in their lifetime, there will be at least 1.75 billion potential cancer tests. Thirdly, these countries enable CST to focus regionally, addressing practical considerations such as overheads and supply chain integrity... we all remember the disruption to global supply chains during COVID. Finally, Lung, Liver, Colon & Nasopharynx cancers are the top four major cancers in Asia. The fact is, there are no IVD commercial cancer tests in the world today for Lung & Nasopharynx cancer... except CST’s test. That is a marketers dream come true. On top of that though, Asia has the highest rates of lung cancer in the world today. A well-known fact is that smoking is the cause of 80% of all lung cancers. But a little known fact is that 46% of the world’s smokers live in just two countries; India & China! Initially, CST’s marketing focus will be on tests for those four major cancers. Strategically, this is a very smart decision by CST , because it provides a single minded focus for marketing, and it also conveys a clear product line image to the market that the market can focus on. Any resultant positive tests for other cancers will simply add to the credibility of CST’s products, and the market itself will drive sales towards those other cancer types.” Male Host: “This sounds like a plan formulated by some very smart people who understand the market and the region. ” Female Host: “Yes, I was impressed I must say... and I am very confident CST’s management have laid the foundations for executing a well thought out strategy to capture the market they are aiming for. ” Male Host: “Well, I think it is now time to sum up don’t you?” Female Host: “I agree, so let me start, because as I said before, I think marketing and distribution are critical factors for CST’s success.” Male Host: “You have the microphone... (Male Host laughs).” Female Host: “If CST singularly focused on just four cancers (Lung, Liver, Colon & Nasopharynx), in the Asian Region alone, I believe CST will build a wildly successful (by all metrics) biomedical company.” Male Host: “I could not agree more. ” Female Host: “When you add to that, CST’s ability to detect 24 major cancers using a Saliva based platform that is a global mass population... fast... non-invasive... cheap - but accurate cancer test, it is very hard not to imagine entrepreneurial rates of return for CST’s investors. ” Male Host: “I can only agree with you once again... I will add that one of the things we had not covered, but it did impress me, is that CST is not trying to reinvent the wheel... production and manufacturing will be outsourced to reputable large volume specialty companies based in Australia... and one of those companies is the company CST plans to merge with to create the listed entity we have already talked about... a perfect fit.” Female Host: “I am not sure how we missed those points, so I am glad you remembered because they are important components of CST’s business plan. Anything else you can think of?” Male Host: “I think it is probably important to remind everyone that CST’s Phase 2 Saliva Cancer test will provide a personalised Artificial Intelligence generated genomic profile of a patient’s cancer to help navigate appropriate personalised treatment, thus ensuring the best possible outcome for each individual patient.” Female Host: “That was a very important point to remind everyone of... I truly believe personalised medicine is the future of medicine.” Male Host: “And I believe Rapid Point-of-Care and Over-the-Counter Saliva based Cancer Tests are a revolution in cancer diagnostics. That’s the future ... and CST’s saliva cancer test is well positioned to deliver on their business plan to secure, I think, a conservative year 5 valuation of 558 million dollars ... and I might point out, without the Stock Exchange Listing, so it should be multiples of that with a stock exchange listing.” Female Host: “I think that is a great way to close.” Male Host: “I think it is too... We are impressed with CST’s products, and we believe we are going to be hearing a lot more about CST in the media as soon as their saliva products are announced and released to the world ... because their products are really going to help save people’s lives.” Female Host: “I love a positive story.” Male Host: “Me too... Thank you for listening or watching everyone.”